α and 1–β [Power / Sample Size]

posted by Yura – Belarus, 2017-12-28 05:50  – Posting: # 18108
Views: 23,613

Hi Helmut,

» Although the study was performed with 28 subjects for ~81% power, the chance to get a post hoc power of ≥ 90% is ~23% and ≥ 95% is ~10%. That’s clearly not “forced BE” and none of these studies should be questioned by regulators.

You are considering the power after the study at n = 28 (which were calculated before the study: GMR=0.95, CV=0.25, β=0.80). The question is whether it is possible to carry out a study at n = 50 and will this be forced bioequivalence?
Regards

Complete thread:

Activity
 Admin contact
20,254 posts in 4,262 threads, 1,398 registered users;
online 16 (0 registered, 16 guests [including 7 identified bots]).
Forum time (Europe/Vienna): 04:47 UTC

You should treat as many patients as possible with the new drugs
while they still have the power to heal.    Armand Trousseau

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5